SVB Wealth LLC Purchases Shares of 18,981 Dr. Reddy’s Laboratories Limited (NYSE:RDY)

SVB Wealth LLC purchased a new stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY) in the 4th quarter, HoldingsChannel.com reports. The fund purchased 18,981 shares of the company’s stock, valued at approximately $300,000.

Several other large investors have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC grew its stake in shares of Dr. Reddy’s Laboratories by 43.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock valued at $36,000 after purchasing an additional 137 shares during the period. Van ECK Associates Corp grew its stake in shares of Dr. Reddy’s Laboratories by 64.3% in the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock valued at $64,000 after purchasing an additional 322 shares during the period. Lifestyle Asset Management Inc. grew its stake in shares of Dr. Reddy’s Laboratories by 3.2% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 13,689 shares of the company’s stock valued at $1,088,000 after purchasing an additional 422 shares during the period. Natixis Advisors LLC grew its stake in shares of Dr. Reddy’s Laboratories by 7.2% in the 3rd quarter. Natixis Advisors LLC now owns 10,937 shares of the company’s stock valued at $869,000 after purchasing an additional 735 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in shares of Dr. Reddy’s Laboratories in the 3rd quarter valued at approximately $60,000. Institutional investors and hedge funds own 3.85% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Nomura lowered Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. Barclays lowered their price objective on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Finally, StockNews.com lowered Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th.

Dr. Reddy’s Laboratories Stock Up 0.8 %

NYSE RDY opened at $12.92 on Thursday. The firm has a market cap of $10.78 billion, a PE ratio of 20.57 and a beta of 0.50. Dr. Reddy’s Laboratories Limited has a one year low of $12.62 and a one year high of $16.89. The stock’s 50 day simple moving average is $14.34 and its 200 day simple moving average is $15.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. As a group, sell-side analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.